193 related articles for article (PubMed ID: 34406581)
21. Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients.
Shumock SS; Temple WC; Marinoff A; Aaronson K; Southworth E; Xirenayi S; Lee AG; Leung SG; Sweet-Cordero EA; Hermiston M; Higham C; Stieglitz E
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1901. PubMed ID: 37933765
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
Short NJ; Jabbour E; Nasr LF; Jain N; Haddad FG; Issa GC; Sasaki K; Senapati J; Kebriaei P; Garris R; Konopleva M; Ravandi F; Kantarjian H
Am J Hematol; 2024 Jul; 99(7):1423-1426. PubMed ID: 38607091
[No Abstract] [Full Text] [Related]
23. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
Yoshimura S; Panetta JC; Hu J; Li L; Gocho Y; Du G; Umezawa A; Karol SE; Pui CH; Mullighan CG; Konopleva M; Stock W; Teachey DT; Jain N; Yang JJ
Leukemia; 2023 Jun; 37(6):1194-1203. PubMed ID: 37076694
[TBL] [Abstract][Full Text] [Related]
24. Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan.
Takahashi N; Kondo T; Ikari Y; Fukumoto Y; Hatake K; Masunari A; Nishibayashi S; Kageyama A; Fukuta Y; Tojo A
Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38747937
[TBL] [Abstract][Full Text] [Related]
25. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Othman T; Koller P; Tsai NC; Yang D; Pourhassan H; Agrawal V; Ngo D; Chen J; Farol L; Spielberger R; Sahebi F; Al Malki MM; Cai JL; Sandhu KS; Mansour J; Salhotra A; Ali H; Aribi A; Arslan S; Marcucci G; Forman SJ; Stein AS; Nakamura R; Pullarkat V; Aldoss I; Mei M
Am J Hematol; 2024 May; ():. PubMed ID: 38804599
[TBL] [Abstract][Full Text] [Related]
26. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
Garcia Molina A
Farm Hosp; 2024 Apr; ():. PubMed ID: 38679535
[TBL] [Abstract][Full Text] [Related]
27. A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia.
Galimberti S; Abruzzese E; Luci G; Baratè C; Luciano L; Iurlo A; Caocci G; Morganti R; Stefanelli F; Di Paolo A
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543276
[TBL] [Abstract][Full Text] [Related]
28. Endothelial function in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors is not related to cardiovascular risk assessed by SCORE2 algorithm.
Szczepanek E; Marczyk B; Chukwu O; Chlopicki S; Sacha T
Pol Arch Intern Med; 2024 Apr; ():. PubMed ID: 38572907
[TBL] [Abstract][Full Text] [Related]
29. Ponatinib Induces a Procoagulant Phenotype in Human Coronary Endothelial Cells via Inducing Apoptosis.
Krajcsir B; Pócsi M; Fejes Z; Nagy B; Kappelmayer J; Beke Debreceni I
Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675220
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1-positive acute lymphoblastic leukemia.
Walczak P; Fodil S; Vignal N; Cabannes-Hamy A; Boissel N; Raffoux E; Cayuela JM; Goldwirt L; Lengliné E
Blood; 2024 Jun; ():. PubMed ID: 38917352
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study.
Chen MT; Huang ST; Lin CW; Ko BS; Chen WJ; Huang HH; Hsiao FY
Oncologist; 2021 Nov; 26(11):974-982. PubMed ID: 34418220
[TBL] [Abstract][Full Text] [Related]
32. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Cortes J; Apperley J; Lomaia E; Moiraghi B; Undurraga Sutton M; Pavlovsky C; Chuah C; Sacha T; Lipton JH; Schiffer CA; McCloskey J; Hochhaus A; Rousselot P; Rosti G; de Lavallade H; Turkina A; Rojas C; Arthur CK; Maness L; Talpaz M; Mauro M; Hall T; Lu V; Srivastava S; Deininger M
Blood; 2021 Nov; 138(21):2042-2050. PubMed ID: 34407543
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary hypertension in patients with chronic myeloid leukemia.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Sun BJ; Park JH; Jeong JO; Jo DY
Medicine (Baltimore); 2021 Aug; 100(33):e26975. PubMed ID: 34414970
[TBL] [Abstract][Full Text] [Related]
34. A Case of Tyrosine Kinase Inhibitor-Induced Bone Marrow Aplasia That Was Successfully Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Kamijo K; Shimomura Y; Yamashita D; Ishikawa T
Case Rep Oncol; 2021; 14(2):1139-1143. PubMed ID: 34413745
[TBL] [Abstract][Full Text] [Related]
35. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
[TBL] [Abstract][Full Text] [Related]
36. Management of Adverse Events Associated With Tyrosine Kinase Inhibitor Use in Adult Patients With Chronic Myeloid Leukemia in Chronic Phase: An Advanced Practice Perspective.
Bauer S; Comer H; Ramsey B; Thomas K
J Adv Pract Oncol; 2021 Jul; 12(5):521-533. PubMed ID: 34430062
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sugiura I; Doki N; Hata T; Cho R; Ito T; Suehiro Y; Tanaka M; Kako S; Matsuda M; Yokoyama H; Ishikawa Y; Taniguchi Y; Hagihara M; Ozawa Y; Ueda Y; Hirano D; Sakura T; Tsuji M; Kamae T; Fujita H; Hiramoto N; Onoda M; Fujisawa S; Hatta Y; Dobashi N; Nishiwaki S; Atsuta Y; Kobayashi Y; Hayakawa F; Ohtake S; Naoe T; Miyazaki Y
Blood Adv; 2022 Jan; 6(2):624-636. PubMed ID: 34516628
[TBL] [Abstract][Full Text] [Related]
38. Skeletal muscle metastasis from a gastrointestinal stromal tumor: A case report.
Zhu G; Sun W; Liu Y; Wang H; Ye S
Medicine (Baltimore); 2021 Aug; 100(34):e27011. PubMed ID: 34449472
[TBL] [Abstract][Full Text] [Related]
39. A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors.
Singh AS; Hecht JR; Rosen L; Wainberg ZA; Wang X; Douek M; Hagopian A; Andes R; Sauer L; Brackert SR; Chow W; DeMatteo R; Eilber FC; Glaspy JA; Chmielowski B
Clin Cancer Res; 2022 Jan; 28(1):84-94. PubMed ID: 34407970
[TBL] [Abstract][Full Text] [Related]
40. Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors.
Satoh K; Morisawa S; Okuyama M; Nakae H
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
